UPB

Upstream Bio (UPB)

About Upstream Bio (UPB)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Details

Daily high

$29.72

Daily low

$26.03

Price at open

$26.92

52 Week High

$33.00

52 Week Low

$5.14

Market cap

1.5B

Dividend yield

0.00%

Volume

932,274

Avg. volume

544,389

P/E ratio

-11.91

Upstream Bio News